HRA's ellaOne gets nod from CHMP as first emergency contraceptive

HRA Pharma, a privately-held, French pharmaceutical firm, says that the Committee for Medicinal Products for Human Use (CHMP) of the  European Medicines Agency (EMEA) has issued a positive opinion  recommending marketing authorization for ellaOne (ulipristal  acetate), its next-generation emergency contraceptive. If cleared,  ellaOne will be the first product to have been specifically designed  for use as an emergency contraceptive. According to the Paris-based  company, the drug presents improved clinical characteristics over  existing hormonal treatments, such as a good safety and tolerability  profile and the advantage of sustained efficacy up to five days  following unprotected intercourse or contraception failure.